Caplin Point (CAPLIPOINT) | Stock Overview & Key Data
Caplin Point Performance Comparison
Stock Range
Today's Range
Low: ₹2,165.00
High: ₹2,259.90
on September 25, 2025
52 Week Range
Low: ₹1,599.00
High: ₹2,641.00
on April 7, 2025
on December 27, 2024
All-Time High: ₹2,641.00 on December 23, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR171.4B
EPS
74.04
P/E Ratio (TTM)
31.33
Forward P/E
22.51
P/B Ratio
6.35
PEG Ratio
1.35
Div. Yield
0.38%
ROE
18.58%
Beta
0.025
Debt to Equity
0.17
Financial Highlights
Profitability
Gross Margin
61.73%
Operating Margin
31.65%
Profit Margin
28.42%
Returns and Earnings
Return on Assets (TTM)
16.72%
Return on Equity (TTM)
18.58%
EBITDA
INR7.7B
Net Income (TTM)
INR5.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR261.63
Quarterly Revenue Growth (YoY)
11.20%
Quarterly Earnings Growth (YoY)
23.30%
Dividend Information
Last 12-Month Dividend
₹8.50
Current Dividend Yield
0.38%
3-Year Average Dividend Yield
0.19%
3-Year Average Annual Dividend
₹5.83
3-Year Total Dividends
₹17.50
Ex-Dividend Date
September 12, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Caplin Point CAPLIPOINT | 171.42B Mid-cap | -5.94% | 0.99% | 3.59% | 6.19% | -13.08% | 14.18% | 193.34% | 292.42% |
| Sun Pharmaceutical SUNPHARMA | 3.94T Large-cap | 0.43% | -1.79% | -2.08% | -8.84% | -13.91% | -16.50% | 71.52% | 220.99% |
| Divi's Laboratories DIVISLAB | 1.63T Large-cap | -3.52% | -5.63% | -10.47% | 0.96% | -2.90% | 8.05% | 59.15% | 92.40% |
| Neuland Laboratories NEULANDLAB | 193.78B Mid-cap | -7.01% | 11.06% | 22.65% | 26.15% | 5.10% | 17.45% | 1,001.92% | 1,175.35% |
| Alembic APLLTD | 186.95B Mid-cap | -3.70% | -5.74% | -5.14% | -1.44% | -12.12% | -22.84% | 52.47% | -0.52% |
| Jubilant Pharmova JUBLPHARMA | 172.34B Mid-cap | -2.75% | 0.29% | -3.56% | 20.78% | 0.04% | -7.64% | 221.57% | 96.04% |
Ownership & Short Interest
Insider Ownership
73.29%
Institutional Ownership
4.96%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
123K
Average 90-Day Volume
113K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CAPLIPOINT's 52-week high and low?
- In the last 52 weeks, Caplin Point reached a high of ₹2,641.00 (on December 27, 2024) and a low of ₹1,599.00 (on April 7, 2025).
- What is the market cap and P/E ratio for CAPLIPOINT?
- Curious about Caplin Point's size and valuation? Its market capitalization stands at 171.42B. When it comes to valuation, the P/E ratio (trailing twelve months) is 31.33, and the forward P/E (looking ahead) is 22.51.
- Does CAPLIPOINT pay dividends? If so, what's the yield?
- Yes, Caplin Point is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.38%, and the company has paid an average of ₹5.83 per share annually over the past 3 years.
- Who are Caplin Point's main competitors or similar companies to consider before investing?
When looking at Caplin Point, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.94T Healthcare Drug Manufacturers - Specialty & Generic -16.50% 71.52% Divi's Laboratories
DIVISLAB1.63T Healthcare Drug Manufacturers - Specialty & Generic 8.05% 59.15% Neuland Laboratories
NEULANDLAB193.78B Healthcare Drug Manufacturers - Specialty & Generic 17.45% 1,001.92% Alembic
APLLTD186.95B Healthcare Drug Manufacturers - Specialty & Generic -22.84% 52.47% Jubilant Pharmova
JUBLPHARMA172.34B Healthcare Drug Manufacturers - Specialty & Generic -7.64% 221.57% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Caplin Point Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Caplin Point's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 18.58%, the Debt to Equity ratio from the most recent quarter is 0.17, and its Gross Profit Margin stands at 61.73%.
- What is the recent revenue and earnings growth for CAPLIPOINT?
- Looking at Caplin Point's growth, its revenue over the trailing twelve months (TTM) was INR20B. Compared to the same quarter last year (YoY), quarterly revenue grew by 11.20%, and quarterly earnings saw a YoY growth of 23.30%.
- How much of CAPLIPOINT stock is held by insiders and institutions?
- Wondering who owns Caplin Point stock? Company insiders (like executives and directors) hold about 73.29% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 4.96%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.